Metastasectomy in renal cell cancer after neoadjuvant therapy with multi-tyrosine kinase inhibitors;Metastasenresektion nach neoadjuvanter systemtherapie mit multityrosinkinaseinhibitoren beim metastasierten nierenzellkarzinom

Urologe - Ausgabe A

Volumn 51, Issue 3, 2012, Pages 398-402

  Firek, P ^a   Richter, S ^a   Jaekel, J ^a   Brehmer, B ^a   Heidenreich, A ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Metastasectomy; Neoadjuvant targeted therapy; Renal cell carcinoma; Tyrosine kinase inhibitors

Indexed keywords

ALPHA2A INTERFERON; BEVACIZUMAB; KI 67 ANTIGEN; SUNITINIB; TEMSIROLIMUS;

ARTICLE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SIZE; CANCER SURGERY; CANCER TISSUE; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIVER RESECTION; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS RESECTION; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; PANCREAS METASTASIS; PANCREAS RESECTION; PANCREATITIS; SPLENECTOMY; TREATMENT DURATION; VEIN PROSTHESIS; VEIN SURGERY; WOUND DEHISCENCE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; METASTASECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; NEOPLASTIC CELLS, CIRCULATING; PANCREATIC NEOPLASMS; PROGNOSIS; PROTEIN-TYROSINE KINASES;

EID: 84863785705     PISSN: 03402592     EISSN: 14330563     Source Type: Journal    
DOI: 10.1007/s00120-011-2762-9     Document Type: Article

References (20)

1. Hock LM, Lynch J, Bajaj KC (2002) Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data. J Urol 167(1):57-60 (Pubitemid 34024497)
2. Ries LAG, Melbert D, Krapcho M et al (2008) SEER Cancer Statistics Review, 1975-2005. National Cancer Institute, http://seer.cancer.gov/csr/1975- 2005/
3. Ljungberg B, Hanbury DC, Kuczyk MA et al (2007) European Association of Urology Guideline Group for renal cell carcinoma. Renal cell carcinoma guideline. Eur Urol 51:1502-1510
4. Swanson DA (2004) Surgery for metastases of renal cell carcinoma. Scand J Surg 93(2):150-155 (Pubitemid 38937655)
5. Flanigan RC, Mickisch G, Sylvester R (2004) Cytoreduktive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171:1071-1076 (Pubitemid 38327529)
6. Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584-3590
7. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal- cell carcinoma. N Engl J Med 356(22):2271-2281 (Pubitemid 46849157)
8. NCCN (2010) NCCN Guideline Kidney Cancer, Version 02-2010. NCCN, Jenkintown
9. Kavolius JP, Mastorakos DP, Pavlovich C et al (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16(6):2261-2266 (Pubitemid 28265066)
10. Mickisch G (2002) Principles of nephrectomy for malignant disease. BJU Int 89(5):488-495 (Pubitemid 34415625)
11. Wiesner C, Jakse G, Rohde D (2002) Therapy of local recurrence of renal cell carcinoma. Oncol Rep 9(1):189-192
12. Piltz S, Meimarakis G, Wichmann MW et al (2002) Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 73(4):1082-1087 (Pubitemid 34275883)
13. Lam JS, Belldegrun AS, Figlin RA (2006) Adjuvant treatment for renal cell carcinoma. Expert Opin Pharmacother 7:705-720
14. Patard JJ, Thuret R, Raffi A et al (2009) Treatment with sunitinib enabled complete resection of massive lymphadenopathy not previously amenable to excision in a patient with renal cell carcinoma. Eur Urol 55:237-239
15. Karakiewicz PI, Suardi N, Jeldres C et al (2008) Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 53:845-848 (Pubitemid 351273883)
16. Amin C, Wallen E, Pruthi RS et al (2008) Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 72:864-868
17. Thomas AA, Rini BI, Stephenson AJ et al (2009) Surgical resection of renal cell carcinoma after targeted therapy. J Urol 182(3):881-886
18. Wood CG, Margulis V (2009) Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease. Cancer 115(10):2355-2360
19. Margulis V, Matin SF, Tannir N et al (2008) Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180(1):94-98
20. Oosterling SJ, Bij GJ van der, Mels AK et al (2006) Perioperative IFN-alpha to avoid surgically induced immune suppression in colorectal cancer patients. Histol Histopathol 21(7):753-760 (Pubitemid 44082717)